Furthermore, the unexpected observation that fingolimod, a drug frequently administered to MS patients and targeting sphingosine‐1 phosphate receptors, increases the levels of BDNF in rodent neurons has fueled speculations that some of the beneficial effects of the drug may result from increased BDNF levels.12 Here, BDNF is linked to myeloid sarcoma.